Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

New Drug Combo Could Prevent Head and Neck Cancer in High-Risk Patients

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
A new combination of drugs has demonstrated potential in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck.

“Squamous cell carcinoma of the head and neck [SCCHN] is the most common type of head and neck cancer,” said Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology at Emory University School of Medicine (Atlanta, GA, USA), and director of the Cancer Chemoprevention Program at Winship Cancer Institute at Emory University. “The survival rate for patients with SCCHN is very poor. An effective prevention approach is desperately needed, especially since we can identify patients who are at extremely high risk: those with advanced oral precancerous lesions.”

Based on earlier research suggesting a role for epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in promoting SCCHN, Dr. Shin and colleagues believed combining an EGFR inhibitor and a COX-2 inhibitor could provide an effective chemopreventive approach. They found that the combination of the EGFR inhibitor erlotinib and the COX-2 inhibitor celecoxib was more effective for inhibiting the growth of human SCCHN cell lines compared with either drug alone. Moreover, treating mice with the drug combination prior to transplanting them with human SCCHN cells more effectively suppressed cancer cell growth than did pretreating the mice with either drug alone.

Dr. Shin and colleagues, based on these preclinical analyses, initiated a phase I chemoprevention trial. Eleven patients with advanced oral precancerous lesions were assigned to treatment with erlotinib and celecoxib. Tissue samples from the patients were taken and assessed pathologically at 3, 6, and 12 months after the start of therapy. Biopsies at baseline and follow-up were available for seven patients. The study’s findings, which included preclinical and clinical analyses, were published February 2013 in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Pathologic examination of the biopsies indicated that three of the seven patients had a complete pathologic response; that is, there was no longer evidence of the precancerous lesions in the follow-up biopsy sample. Among the other patients, two had a partial pathologic response and two had progressive disease. “Finding that this drug combination caused some advanced premalignant lesions to completely disappear was great news,” remarked Dr. Shin. “Advanced premalignant lesions rarely regress, so our data are proof-of-principle that a combination chemopreventive strategy with molecularly targeted agents is possible.”

Several patients dropped out of the trial because of severe adverse side effects, according to Dr. Shin. “Prevention is not achieved through short-term treatment,” he said. “So, we need to investigate the safety and toxicity of this combination further before planning a large-scale trial. We are also looking to combination therapies using less toxic or nontoxic agents, such as natural compounds.”

Related Links:

Emory University School of Medicine




comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.